CEPI Expands COVID-19 Vaccine Portfolio, But Pleads For Big Funding Boost
Six Programs Now Under Way
As the coronavirus continues its global spread, the global CEPI partnership is broadening its investment in programs that it hope will result in the rapid development and licensing of new vaccines.
You may also be interested in...
As US cases set to reach half a million, FDA gives green light to blood plasma trials to help meet urgent need for therapies.
Organizations like BARDA, CEPI and others are looking to partner with industry to rapidly test, manufacture, package and deploy vaccines and therapeutics, identifying areas they want to work together during BIO’s recent summit.
Phase III trial could lead to mid-2020 BLA filing to prevent seasonal influenza in adults 65 and older. Novavax also talked up the potential value of its adjuvant in COVID-19 vaccine development.